 ChemoCentryx Inc NASDAQ:CCXI shares are trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis. European Union approval of TAVNEOS represents the third major global sector to recognize the value of this long-awaited new treatment for the debilitating and often deadly disease of ANCA-associated vasculitis, said Thomas J. 